证券代码：002365 证券简称：永安药业 公告编号：2025-33 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 4 月 30 日、2025 年 5 月 6 日连续两 个交易日内日收盘价格跌幅偏离值累计超出 20%，根据深圳证券交易所的有关规 定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 （二）公司于 2025 年 5 月 6 日披露了《关于公司实际控制人、董事长被留 置的公告》（公告编号 2025-31），公司实际控制人、董事长陈勇先生被立案调 查并实施留置，截至本公告披露日，公司暂未知悉上述事项的进展及结论，暂未 收到有权机关对公司的任何调查或者配合调查文件。公司具有完善的组织结构和 规范的治理体系，目前公司生产经营活动正常，公司其他董事、监 ...

最后再强调一句，我是帮主郑重，专注中长线投资20年，以后会经常跟大家唠唠市场里的这些事儿，帮大伙把投资的路看得更清楚。记住了，投资路上别贪 心，合规和稳健才是硬道理。今天这事儿就聊到这儿，咱们下回接着唠！ 不过啊，帮主觉得这事儿有点蹊跷。不知道大家还记得不，就在4月21号到29号那阵子，永安药业7个交易日里整整来了5个涨停板，股价跟坐了火箭似的往 上窜。现在回头看，这波涨停会不会和董事长被查有啥关联呢？是不是有人提前知道了消息在搞动作？这些都得等监管部门进一步调查才能水落石出。 作为中长线投资者，咱得明白一个道理：买股票就是买公司，要是公司的当家人出了问题，那基本面可就像建在沙滩上的房子，说塌就塌。尤其是这种突然 的股价异动背后，往往藏着不少风险。咱选股的时候，得多留个心眼，看看公司治理是否规范，有没有合规隐患，别光盯着短期涨幅就往里冲。 现在这事儿给咱们提了个醒：资本市场不是法外之地，不管多大的老板，只要触犯了规则，就得接受调查。咱们普通投资者啊，还是得把眼光放长远，远离 那些靠炒作起来的"妖股"，多关注真正有业绩支撑、管理规范的企业。 各位朋友大家好，我是帮主郑重，做了20年财经记者的中长线投资者。今天咱 ...

潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第七次临时 会议的会议通知于 2025 年 5 月 5 日以书面、电话、传真、电子邮件等形式送达 公司全体董事，会议于 2025 年 5 月 6 日在公司会议室以通讯方式召开，本次会 议应参与审议表决董事 6 人，实际参与审议表决董事 5 人，缺席董事 1 人（董事 长陈勇先生因暂不能正常履职，缺席本次会议），参会全体董事同意豁免本次会 议通知期限，会议由公司半数以上董事推举董事陈子笛先生主持，会议的召开符 合《公司法》、《公司章程》及《董事会议事规则》的规定，会议以书面记名投 票方式进行表决，通过了如下决议： 审议通过《关于推举公司董事、常务副总经理代为履行董事长职责的议案》 表决结果：同意 5 票，反对 0 票，弃权 0 票。 鉴于公司董事长陈勇先生暂无法履行董事长职责，详见公司于 2025 年 5 月 6 日披露的《关于公司实际控制人、董事长被留置的公告》（公告编号： 2025-31），为了保证公司董事会正常运作和经营决策的顺利开展，维护公司经 营和治理的稳定性，董事会同意由公司董事、常务副总经理陈子笛先生在此期间 代为履行董事长的职责。 上述事项 ...

Group 1 - The company, Qianjiang Yong'an Pharmaceutical Co., Ltd., announced that its actual controller and chairman, Chen Yong, is under investigation and has been detained, leading to a stock price drop and a total market value of 3.424 billion yuan [1] - The company was listed in March 2010 and primarily engages in the research, production, and sales of taurine products, epoxy ethane, and health-related products, as well as investments in the health sector [2] - The company's revenue for the years 2022, 2023, 2024, and the first quarter of 2025 was 1.46245 billion yuan, 972.89 million yuan, 838.81 million yuan, and 171.15 million yuan respectively, with net profit attributable to the parent company showing fluctuations [2] Group 2 - Chen Yong, born in January 1959, is currently 66 years old and received a salary of 2.5741 million yuan for the year 2024 [2] - As of March 31, 2025, Chen Yong directly holds 21.54% of the company's shares, with a market value of 737.5 million yuan [2]

永安药业（002365）一字跌停，公司实际控制人、董事长陈勇被立案调查并实施留置。 ...

机构指出，5月预计风险偏好还有回升空间，A股将继续呈现风偏回暖、主题轮动的特征，以低机构持仓的主题型交易机会为主。 【财经日历】 20:30 美国3月贸易帐 | 因 盘前必读 | // 外盘怎么样 // | | | | --- | --- | --- | --- | | 名称 | 现价 | 涨跌 | 涨跌幅 | | 道琼斯工业指数 | 41218.83 | -98.60 | -0.24% | | 纳斯达克指数 | 17844.24c | -133.49 | -0.74% | | 标普500 | 5650.38 | -36.29 | -0.64% | 当地时间周一，美股三大指数集体收跌，纳指跌0.74%，标普500指数跌0.64%，道指跌0.24%。 美国影视巨头股价"先跌为敬"，奈飞收跌1.94%，派拉蒙跌1.57%，迪士尼跌0.44%。 大型科技股多数下跌，苹果跌超3%，特斯拉跌逾2%，亚马逊、英特尔跌超1%。 热门中概股涨跌不一，纳斯达克中国金龙指数跌0.04%。金山云涨超4%，富途控股、名创优品涨超2%，好未来、微博涨超1%，小鹏汽车、理想汽车、哔哩 哔哩小幅上涨；极氪跌超2%，蔚来、京东跌超1%，腾讯 ...

Group 1 - Heng Rui Pharmaceutical has officially passed the Hong Kong Stock Exchange listing hearing, with the potential to be listed as early as May [1] - The listing represents a significant step in Heng Rui's internationalization strategy, following its IPO in the A-share market [1] - The company aims to leverage the larger growth opportunities in overseas markets as part of its "innovation + internationalization" dual-driven strategy [1] Group 2 - Neuralink's brain-computer interface device Link has received FDA "breakthrough device" designation, aimed at providing communication solutions for patients with severe speech impairments [2] - This designation will expedite the review process, marking a significant advancement for Neuralink in the brain-computer interface field [2] - However, this certification does not equate to market approval, and further clinical validation and safety assessments are required [2] Group 3 - Novo Nordisk's oral version of the weight loss drug Wegovy has had its application accepted by the FDA, with a decision expected in Q4 [3] - If approved, it will be the first oral GLP-1 receptor agonist for chronic weight management globally, potentially enhancing Novo Nordisk's competitive position in the weight loss market [3] - The oral formulation addresses issues of injection adherence among patients, indicating a broad market opportunity if approved [3] Group 4 - Xianju Pharmaceutical has received an administrative penalty of 195 million yuan for engaging in price-fixing agreements that restricted competition in the market for dexamethasone phosphate raw materials [4] - This significant fine reflects the increasing regulatory scrutiny and enforcement against anti-competitive practices in the pharmaceutical sector [4] - The penalty is expected to have a substantial negative impact on Xianju's short-term performance and highlights weaknesses in the company's compliance framework [4] Group 5 - Yong'an Pharmaceutical's chairman Chen Yong is under investigation and has been detained, although the company states that its operations and management remain stable [5] - The investigation may affect the market's perception of the company's credibility and management stability [5] - Despite assurances of normal operations, there may be short-term pressure on the company's stock price due to the uncertainty surrounding the investigation [5]

Group 1: Corporate Investigations and Issues - China Copper Industry Co., Ltd. director Li Lianbing is under investigation for serious violations of discipline and law [3] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong is under investigation and has been detained [6] - Xianju Pharmaceutical received an administrative penalty of 195 million yuan for price-fixing agreements with competitors [10] Group 2: Corporate Transactions and Financial Warnings - AVIC Capital plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Avionics to its controlling shareholder for 4.067 billion yuan [7] - Jiangsu Wuzhong's stock will be subject to additional risk warnings due to an audit report with no opinion and non-operational fund occupation by related parties [8] - Tianmao Group and Jinlitai are both unable to disclose their periodic reports on time, leading to stock suspensions [10][11] Group 3: Industry Trends and Changes - Several automotive companies, including Li Auto, Xiaomi, NIO, and Xpeng, are shifting their marketing language from "smart driving" to "assisted driving" [21]

每经编辑 陈鹏程 王晓波 1 隔夜市场 美股三大指数集体收跌，纳指跌0.74%，标普500指数跌0.64%，道指跌0.24%，道指与标普500指数此前连续9个交易日的上涨至此终结；大型科技股多数下 跌，苹果跌超3%，特斯拉跌逾2%，亚马逊、奈飞、英特尔跌超1%，英伟达小幅下跌；微软、谷歌、Meta小幅上涨；伯克希尔-A跌超5%，巴菲特将于2025 年底卸任首席执行官一职。中概股涨跌不一，纳斯达克中国金龙指数跌0.04%；金山云涨超4%，富途控股、名创优品涨超2%，好未来、微博涨超1%，小鹏 汽车、理想汽车、哔哩哔哩小幅上涨；极氪跌超2%，瑞幸咖啡、蔚来、京东、霸王茶姬跌超1%。 国际油价走弱，美油主力合约收跌1.82%，报57.23美元/桶；布伦特原油主力合约跌1.55%，报60.34美元/桶。 国际金价大幅走高，现货黄金涨2.85%，报3332.85美元/盎司；COMEX黄金期货涨3.09%，报3343.50美元/盎司；COMEX白银期货涨1.29%，报32.68美元/盎 司。 欧洲主要股指收盘涨跌不一，德国DAX指数涨1.12%报23344.54点，法国CAC40指数跌0.55%报7727.93点，英国股 ...

Mergers and Acquisitions - Xingye Yinxin plans to acquire Atlantic Tin Company for approximately 4.54 billion RMB, with a total investment of about 0.98 million AUD at a price of 0.24 AUD per share [1] - Electric Power Investment Energy is undergoing an asset restructuring with its actual controller, State Power Investment Corporation, involving the acquisition of Inner Mongolia Baiyin Hua Coal Power equity [2] - Huibo Yuntong intends to purchase control of Baode Computer System Co., Ltd. through a combination of share issuance and cash payment, with details to be disclosed in a restructuring report [3] Share Buybacks and Increases - Kesi Technology plans to repurchase shares worth between 30 million and 50 million RMB, using self-owned funds for employee stock ownership plans or capital reduction [4] - Fuchuang Precision's major shareholder, Shenyang Advanced Manufacturing Technology Industry Co., Ltd., aims to increase its stake in the company by 1.2 billion to 2.4 billion RMB over the next 12 months [5] Regulatory and Compliance Issues - Yong'an Pharmaceutical's actual controller and chairman, Chen Yong, is under investigation and has been detained, with the company monitoring the situation closely [6] - *ST Gongzhi received a notice of termination of listing due to financial reporting issues, including an audit report with no opinion expressed for the 2024 fiscal year [8] - Xianju Pharmaceutical was fined 195 million RMB for engaging in monopolistic practices related to the pricing of dexamethasone phosphate sodium raw materials [9] - *ST Hengli failed to disclose periodic reports within the legal timeframe, leading to potential termination of its stock listing [10] - Tianmao Group also failed to disclose its periodic reports on time, resulting in stock suspension [11]